The enriched KEGG terms of the downregulated DEGs included prostate cancer (KEGG:05215), EGFR tyrosine kinase inhibitor resistance (KEGG:01521), and the MAPK signaling pathway (KEGG:04010) (Supplementary Figure S1; Supplementary Table S11). This evidence concerns the gene EGFR and prostate carcinoma.